ABSTRACT
BACKGROUND: Lepirudin, a recombinant hirudin, is a direct acting thrombin inhibitor that has been used as a heparin alternative in patients with heparin-induced thrombocytopenia requiring on-pump cardiac surgery. To evaluate the efficacy, safety, and clinical utility of lepirudin as a cardiopulmonary bypass (CPB) anticoagulant, we compared lepirudin with heparin in a routine CPB setting. METHODS: Twenty patients were randomly assigned to receive lepirudin (0.25 mg/kg b. w. bolus and 0.2 mg/kg b. w. added to the CPB priming) or heparin (400 U/kg b. w. bolus) with protamine reversal. Lepirudin and heparin anticoagulation during CPB was monitored using the ecarin clotting time or ACT, respectively and additional lepirudin (5 mg) or heparin (5000 U) boluses were administered. RESULTS: The CPB circuit was performed in both groups without thromboembolic complications. Median blood loss during the first 36 hours was statistically higher ( P = 0.007) in the lepirudin group (1.226 +/- 316 ml) compared to the heparin group (869 +/- 189 ml). One patient of the lepirudin group developed pulmonary embolism 24 hours after surgery. This patient was tested homozygous for the FV-Leiden mutation. CONCLUSION: Lepirudin provides effective CPB anticoagulation but induces a higher postoperative blood loss than heparin. Lepirudin should be restricted to patients undergoing CPB who cannot be exposed to heparin.
Subject(s)
Anticoagulants/therapeutic use , Cardiopulmonary Bypass , Coronary Artery Bypass , Heparin/therapeutic use , Hirudin Therapy , Blood Loss, Surgical , Coronary Artery Disease/surgery , Hirudins/blood , Humans , Intraoperative Period , Middle Aged , Postoperative Hemorrhage/chemically induced , Recombinant Proteins/blood , Recombinant Proteins/therapeutic useABSTRACT
A patient with triple heart valve disease, heparin-induced thrombocytopenia, and terminal renal insufficiency was treated successfully using lepirudin for anticoagulation of cardiopulmonary bypass (CPB) and during the postoperative course. Anticoagulatory monitoring was performed with ecarin clotting time during CPB and aPTT postoperatively.
Subject(s)
Cardiopulmonary Bypass/methods , Heart Failure/surgery , Heparin/adverse effects , Kidney Failure, Chronic/complications , Myocardial Ischemia/surgery , Thrombocytopenia/chemically induced , Aged , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Female , Follow-Up Studies , Heart Failure/complications , Hirudins , Humans , Recombinant Proteins/therapeutic use , Thrombocytopenia/complicationsABSTRACT
BACKGROUND: A variety of local treatment modalities exists for the palliative therapy of inoperable primary or secondary liver tumours. In this connection the promising use especially of thermal ablation methods has been reported recently. Numerous procedures and technical terms have been mentioned in this context giving us the opportunity of a review on this subject. METHODS: From the literature of the last five years (Medline/PubMed) including the lists of references physical principles and application techniques, indications and contraindications, possibilities of evaluation and results of high frequency thermotherapy (HFTT) respectively radiofrequency ablation (RFA) were investigated and compared to our own first experiences. Survival and recurrence rates were estimated from the study results. RESULTS: Most authors describe the HF-thermoablative treatment as a technically uncomplicated and relatively low-risk procedure. After a mean follow-up of about 10 months the mean survival rate was about 90 % and tumor recurrence was seen in approximately 30 % of the patients. The main problems occurred in view of the complete registration of all tumors with imaging techniques before RFA and the complete ablation, especially of larger tumours. CONCLUSIONS: In most of the clinical studies RFA promises an advantage of survival and improvement of quality of life compared to the known courses of untreated liver tumours. Therefore this method should be practiced on a larger scale in suitable patients. At the same time its efficacy must be proven by comparative studies.
Subject(s)
Carcinoma, Hepatocellular/therapy , Catheter Ablation , Leiomyosarcoma/therapy , Liver Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/mortality , Colorectal Neoplasms , Female , Follow-Up Studies , Humans , Hyperthermia, Induced , Leiomyosarcoma/mortality , Leiomyosarcoma/secondary , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Male , Middle Aged , Palliative Care , Time FactorsSubject(s)
Cardiopulmonary Bypass , Fibrinolytic Agents/administration & dosage , Hirudins/administration & dosage , Drug Monitoring/methods , Fibrinolytic Agents/blood , Hirudins/blood , Humans , Partial Thromboplastin Time , Recombinant Proteins/administration & dosage , Recombinant Proteins/bloodABSTRACT
UNLABELLED: Allogeneic blood requirements in cardiac surgery shows a wide variation even for comparable procedures. The aim of the present study was to compare the intraoperative allogeneic blood requirement in defined cardiac operations among 12 cardiac centers in Germany. METHOD: A data set with 25 variables concerning the intraoperative course in adult cardiac patients with myocardial revascularization, valve replacement (aortic or/and mitral valve) or combined procedures was distributed to the participating centers. The data of all patients between January 1th 1998 and June 30th 1998 were included. Besides demographic data, the intraoperative transfusion of allogeneic and autologous blood, fresh frozen plasma and the concomitant hematocrit values were registered. Data were analyzed for all centers and separated for each center. RESULTS: The data of 7,729 patients were analyzed. The intraoperative allogeneic blood requirement was 0.6 +/- 1.3 units for all patients. It varied among the centers from 0.25 +/- 0.6 units to 0.97 +/- 1.6 units (P < 0.05). The percentage of patients receiving allogeneic blood was 27% and differed among the centers from 17% to 35%. Female patients were transfused in 53% (36-39%) compared to male patients with 16% (9-20%) (P < 0.05). The rate of autologous blood predonation varied from 0.5% to 23%. Patients without autologous predonation were transfused in 28% compared to 4% in patients with predonation (P < 0.05). In patients with autologous predonation the intraoperative transfusion of allogeneic blood was significantly reduced (0.1 +/- 0.39 vs 0.6 +/- 1.4 units, P < 0.05). However, some centers with a high percentage of autologous predonation also demonstrated a high rate of perioperative allogeneic transfusion. CONCLUSION: The incidence of allogeneic blood transfusion in cardiac surgery depends on the institution and not on the surgical procedure. A common threshold value of hemoglobin for the transfusion of blood trigger even for comparable procedures could not be detected among the centers. Especially in female patients, there was a wide variation in allogeneic blood transfusion. Autologous blood predonation reduces blood requirement significantly, however, it is practiced with variing intensity. The data set did not include information about transfusion regimen in the postoperative period, thus, these data do not allow to draw conclusions for the whole perioperative period.
Subject(s)
Blood Transfusion , Cardiac Surgical Procedures , Adult , Blood Transfusion, Autologous , Female , Germany , Heart Valves/surgery , Hematocrit , Hemoglobinometry , Humans , Intraoperative Period , Male , Myocardial RevascularizationSubject(s)
Anticoagulants/therapeutic use , Fibrinolytic Agents/therapeutic use , Heparin/therapeutic use , Hirudin Therapy , Anticoagulants/administration & dosage , Blood Coagulation/drug effects , Cardiac Surgical Procedures , Cardiopulmonary Bypass , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/blood , Heparin/administration & dosage , Hirudins/administration & dosage , Hirudins/blood , Humans , Injections, Intravenous , Recombinant ProteinsSubject(s)
Aortic Valve Stenosis/surgery , Bioprosthesis , Cardiopulmonary Bypass , Heart Valve Prosthesis , Hirudin Therapy , Platelet Aggregation Inhibitors/therapeutic use , Aged , Aortic Valve/surgery , Blood Platelets/drug effects , Female , Heparin/administration & dosage , Humans , Platelet Aggregation/drug effects , Recombinant Proteins/therapeutic useSubject(s)
Alfentanil , Anesthesia, Intravenous , Carbon Dioxide/pharmacology , Cardiopulmonary Bypass , Cerebral Arteries/physiology , Fentanyl , Methohexital , Midazolam , Acid-Base Equilibrium , Adult , Alfentanil/administration & dosage , Blood Flow Velocity/drug effects , Body Temperature , Carbon Dioxide/blood , Cerebral Arteries/drug effects , Cerebrovascular Circulation/drug effects , Fentanyl/administration & dosage , Humans , Hydrogen-Ion Concentration , Hypothermia, Induced , Methohexital/administration & dosage , Midazolam/administration & dosageABSTRACT
Tricyclic antidepressants (TAD) are administered for therapy of nearly all types of depression. Interactions with anaesthetics are well known and are reported frequently in the literature. A case report about incidental findings from a series of experimental anaesthesias in healthy volunteers using different inhalation anaesthetics is presented enabling discussion of the problem of a possibly increased risk of anaesthesia in the presence of chronic TAD medication. 16 unpremedicated healthy subjects (mean age 27 +/- 4 y) received, at intervals of four weeks, inhalation anaesthesia by breathing spontaneously one of the volatile anaesthetics halothane, enflurane, or isoflurane in oxygen. The aim of the study was to investigate the influence of volatile anaesthetics on the human electroencephalogram. When evaluating the results an atypical increase of heart rate during anaesthesia was noticed in one subject. This tachycardia appeared during all three types of anaesthesia, all other observed parameters being normal. With the knowledge of these facts the volunteer was interviewed more thoroughly. He then admitted to have taken daily 125-175 mg of the TAD amitriptyline during the whole period of experiments (self-medication from lover's grief). We supposed therefore that the tachycardia during anaesthesia could be interpreted as an interaction between the TAD amitriptyline and the volatile anaesthetics halothane, enflurane, and isoflurane. After having discontinued TAD medication for some months, the volunteer, a medical student, repeated the experimental isoflurane anaesthesia with all other conditions identical. This time his heart rate did not differ from that of the other subjects.(ABSTRACT TRUNCATED AT 250 WORDS)